Human hybridomas were constructed which produce antibodies against three different extracts of Mycobacterium leprae. A thioguanine-resistant (Thgr), ouabain-resistant (Ouar), human lymphoblastoid cell line, KR-4, was hybridized with Epstein-Barr virus-transformed cell lines from lepromatous leprosy patients with fusion frequencies of >10-5. Non-Epstein-Barr virus-transformed donor cells fused at much lower rates (<2 x 10-7).
Antigenic analysis of Mycobacterium leprae, the poorly understood causative agent of leprosy, has proceeded rapidly in recent years with the advent of armadillo-grown bacilli (19) . Rabbit antisera revealed seven distinct components in sonic extracts of M. Ieprae, but all seven crossreacted with other species of mycobacteria, as revealed by crossed-immunoelectrophoresis (9) . Others have uncovered protein antigens such as 21B (21) , antigen 7 (11), 12,000-and 33,000-molecular-weight glycoproteins (5) and uncharacterized proteins (1, 4) which have incomplete levels of M. leprae specificity. The hybridoma technique of Kohler and Milstein (16) has produced much more specific monoclonal antibody probes than heterologous antisera. Two monoclonal antibodies have been produced which react specifically with unidentified components of M. Ieprae (8) and another recognizes a 12,000-molecular-weight protein (15) . Perhaps those of greatest interest recognize the terminal saccharide (3,6-di-O-methyl glucose) in a phenolic glycolipid of M. leprae (30) . These monoclonal antibodies are M. leprae specific and do not react with similar structures from other species such as M. kansasii. Others have previously shown that M. leprae contains in its surface capsule, a unique carbohydrate portion consisting of a terminal 3,6-di-O-methyl glucose linked P 1--4 to 2,3-di-Omethyl rhamnose which is linked a 1-*2 to 3-0-methyl rhamnose (13, 14) . Sera from patients infected with M. leprae but not other mycobacterial species also react with this antigen in a disease-and stage-specific manner (2, 3, 6, 23, 29) .
Murine monoclonal antibodies have been valuable mo-lecular probes in these studies, but human hybridomas offer several advantages. First, the construction of human hybridomas will allow development of an antigenic map of M. leprae, as recognized by the human, rather than the murine, immune specificity repertoire. It is conceivable that the human immune system may recognize some novel antigenic determinants since patients, unlike mice, are infected with living, metabolizing organisms. Second, lepromatous leprosy (LL) patients are highly immune and this circumvents the need for using large quantities of a limited M. Ieprae stock in immunizing mice. Third, specific human monoclonal immunoglobulin M (IgM) might enhance the efficacy of the armadillo leprosy vaccine since similar monoclonal antibodies in mice potentiated both the primary and memory response to malaria vaccine, as revealed by enhanced survival after a lethal challange infection (12) . Fourth, the production of anti-M. leprae human monoclonal antibodies is the first step in producing monoclonal human anti-idiotypic reagents which could potentially serve as vaccine replacements, as demonstrated in the case of African trypanosomiasis where administration of anti-Id in the absence of antigen protected against a subsequent challenge with pathogen (25) . If monoclonal antibodies of this type are contemplated for human use, then the experience in the cancer field would suggest that human monoclonal antibodies could overcome the immunogenicity complication of mouse monoclonal antibodies (22) .
In the present study, we used humoral response of LL patients to immortalize the human anti-M. Ieprae A purified phenolic glycolipid (phen-GLIP-I) preparation from M. leprae (14) was generously provided by P. Brennan and judged to be highly pure from thin-layer chromatography analysis. The deacylated derivative of phenolic-glycolipid I (16) was generously provided by D. B. Young (Seattle Public Health Hospital, Seattle, Wash.). Crude lipid preparations from other mycobacteria were prepared in our laboratory according to the method of Reggiardo et al. (24) . Briefly, freeze-dried mycobacteria were suspended in chloroformmethanol (2:1) and extracted at 50°C for 18 h in screw-cap tubes. Extracts were then centrifuged at 1,000 x g for 30 to 40 min to obtain total soluble lipids that were dried under nitrogen and kept at 4°C. Further extraction was done immediately before each screening experiment with carbonate-bicarbonate buffer (pH 9.6) containing 1 mg of sodium deoxycholate per ml, followed by incubation at 56°C for 20 min. 50 ,ul of lipid extracted from the equivalent of 100 ,ug of mycobacteria per ml. Antigen was dissolved in carbonatebicarbonate buffer, pH 9.6, containing 1 mg of sodium deoxycholate per ml. After wells were washed and blocked with 3% bovine serum albumin in PBS for 1 h at 37°C, culture supernatants were added and left for 1 to 2 h at 37°C and thereafter treated in the same manner as the ELISA experiments described above.
In all ELISA experiments, duplicate control wells consisted of (i) wells coated with buffer but lacking antigen and (ii) wells coated with antigen and LL serum at 1:500 added (positive controls) or 20% FCS in RPMI (negative controls).
Immunoglobulin assays. Polystyrene wells were coated with the F(ab')2 fragment of rabbit anti-human immunoglobulin (Cappel Laboratories Inc.) at 1:1,000 in carbonate-bicarbonate buffer, pH 9.6, for 3 h at 37°C. Wells were washed, and after nonspecific binding sites were blocked with 1% bovine serum albumin-PBS for 90 min at 37°C, appropriate dilutions of purified IgG or IgM (Cedarlane Laboratories) or culture supernatants were added. After overnight incubation at 4°C, alkaline phosphataseconjugated goat anti-human IgG (y-chain specific) or anti-human IgM (,u-chain specific) (Cedarlane Laboratories) were added to the appropriate wells, and after a 2-h incubation and washing, p-nitrophenyl phosphate was added and absorbances were recorded as described above. Screening for anti-M. leprae antibody production. Hybrids were screened for antibody by using three different extracts of M. Ieprae. In preliminary experiments, the ELISAs were validated by using LL sera, normal sera, and LL sera absorbed with M. leprae or other mycobacteria (T. Atlaw, M.Sc. thesis, Queen's University, Kingston, Ontario, Canada, 1983). Typical positive and negative control optical density values at 405 nm were, respectively, 0.80 and 0.01 for MLS, 1.0 and 0.01 for MSE, and 0.3 and 0.05 for phen-GLIP-I. Of a total of 1,760 growth-positive hybridoma wells that were screened, 131 hybrids (7.4%) produced anti-M. leprae sonic extract (MLS) antibodies and 240 hybrids (13.6%) produced antibodies against the SDS extract of insoluble cell walls (MSE). Of 176 wells, 9 (5.1%) produced antibodies against phenolic glycolipid from M. leprae (Table 2) .
RESULTS
Cloning. Hybrids whose supernatants were positive in the ELISA were transferred to 24-well Costar plates, grown in medium containing 15% FCS, and then subcultured at 10 cells per well. Of 3,313 wells screened against all three M. leprae extracts, 7 to 11% were positive for antibody (Table   TABLE 3 3). Some of these cells were cloned by limiting dilution at 0.5 cells per well. A total of 2,200 clones were screened, and 148 (6.7%) were positive for anti-MLS and 211 (9.6%) were positive for anti-MSE antibody production ( Table 4) . Of 168 clones, 21 (12.5%) produced anti-phen-GLIP-I antibody.
Specificity. To investigate the specificity of the antibodies produced by the anti-M. leprae clones, crude extracts from four other mycobacteria (M. tuberculosis, M. bovis BCG, M. smegmatis, and M. phlei) were used in parallel screening experiments. These species have been shown in numerous studies to share many antigens with M. leprae (8-11, 28, 30) . Results from representative clones are shown in Table 5 . Of the total 122 clones screened against the five mycobacteria, 9 showed reactions restricted to M. leprae MLS, as illustrated by clones 5E and 8A, or to M. leprae MSE, as illustrated by clones 2C and 2D. Clone 3A and 4A reacted to both extracts of M. leprae, but were negative for all the other mycobacteria. At the other end of the spectrum, a non- specific clone, 83, produced antibodies to both extracts from every mycobacterium tested. Of a total of 58 clones screened, none showed specificity to M. leprae glycolipid antigen, since the seven representative clones shown in Table 6 also reacted with crude lipid extracts from at least one other species. Since we were comparing crude and purified antigens, negative reactions should be interpreted with caution. In both experiments (Tables 5 and 6) , OD values of >3 times background were considered positive. Positive wells were usually .6 times background. Four of the hybridomas reacting with purified phen-GLIP-I also reacted with its deacylated derivative ( Table 7) . O.D. values obtained at high supernatant concentration were similar to those given by a murine hybridoma at low concentrations. The murine hybridoma has a known binding Normal human serum (n = Antibody class. IgM was the major immunoglobulin produced by three anti-M. leprae reactive clones (Table 8) .
Various amounts of IgM (0.1 to 10 p.g/ml) and almost no IgG (0.03 ,ug/ml) were secreted.
Stability. Two randomly selected clones (83 and 40) produced anti-M. leprae antibodies in relatively high quantities for up to 10 weeks in culture, compared to clone 32 which showed a decline of antibody production beginning at week 4 in culture. All three clones studied were fast growing, with a doubling time of 20 to 24 h (Fig. 1) . The reason for increasing antibody production in clones 83 and 40 is not clear, but it could be related to selection for fast-growing cells.
EBV-immortalized clones. EBV lines from three of the four LL patients were cloned at densities of 1 or 10 cells per well and screened for anti-M. Ieprae antibody production. This was done in an attempt to establish a line enriched for specific antibody-producing B-cells that could later be fused to produce hybrids with a much higher frequency of stable antibody production. A total of 10,000 clones of LL-EBV lines were screened, and only 42 (0.42%) were initially positive for anti-M. leprae antibody production against MLS or MSE. Upon retesting, only eight clones were still producing anti-M. leprae antibodies. These were grown in larger flasks, but the property of antibody production was lost gradually within 6 to 16 weeks (data not shown).
DISCUSSION
The results presented here demonstrate the feasibility of producing human monoclonal antibodies specific for M. leprae antigens by using peripheral blood lymphocytes from leprosy patients as donor cells. Ten of the hybridomas reacted with purified phen-GLIP-I, the trisaccharide of which is unique to M. leprae (11) .
The use of EBV transformation alone, without hybridization, has yielded human monoclonal antibodies against some antigens (17, 31) . However, only a few (42) anti-M. leprae clones were identified in the present study among 10,000 EBV-transformed clones from LL patients, and these lost their antibody-producing capacity within 6 weeks of culture. Loss of antibody production was previously observed at month 8 of culture in a clone of anti-tetanus toxoid-specific cells (17) . In the present study, anti-M. leprae antibody production was rescued by fusion with KR-4, and hybridomas were stable beyond 12 months of continuous culture after two cloning cycles. The Ouar Thgr fusion partner KR-4 showed a 20-fold preferential hybridization to EBV-transformed donor lymphocytes compared to non-EBV-transformed lymphocytes from LL patients. Subculturing hybridomas at 10 cells per well after fusion, followed by a single cloning step for those anti-M. Ieprae-reactive wells, did not yield an increased percentage of anti-M. leprae reactive clones as expected, implying that hybridomas are initially unstable but stablize with time. EBV immortalization has several additional advantages since it allows one to repeat fusions on the same patient and produce and store large banks of EBV lines for eventual fusions. In addition, EBV is a polyclonal activator (20) and aids in the expansion of rare antigen-specific B cells before fusion.
The predominant class of antibody secreted by three (12) . Small amounts of monoclonal antimalaria IgM potentiated both the primary and memory response to vaccination, as was revealed by enhanced survival after a lethal challenge infection. The human monoclonal antibodies described here could conceivably enhance the human response to the armadillo leprosy vaccine. Most hybridomas produced were specific for antigens shared by a number of mycobacteria, as expected, since earlier studies with conventional antisera have documented extensive cross-reactions between different mycobacterial species (8-11, 26-28, 30) . However, in a limited panel of mycobacteria, 9 clones of 122 reacted with undefined watersoluble or SDS-soluble antigens in M. leprae sonic extracts. Screening on a larger panel of mycobacterial species is necessary to establish the specificities involved. Several hybridomas reacted with a phen-GLIP-I extract of M. leprae and its deacylated derivative. Therefore the mycocerosic acids of phen-GLIP-I do not appear to be involved. The trisaccharide unit of these molecules is unique to M. leprae and binds only to serum antibodies from leprosy patients and not from normal subjects or patients infected with other mycobacteria (2, 3, 6, 23, 29) . However, all of these clones reacted with crude lipid isolated from at least one other species of mycobacteria, and therefore, the determinants recognized are not unique to M. Ieprae. It is likely, therefore, that our hybridomas react with the genus-specific segment of this molecule, i.e., the phenolic phthiocerol core which is shared among the mycobacterial species, and further experiments have been designed to test this possibility. In contrast, reactivity of a murine hybridoma specific for phen-GLIP-I trisaccharide is restricted to M. leprae (30) . Further experiments are in progress to determine whether binding of human monoclonal G8 to deacylated phen-GLIP-I can be competitively inhibited by a murine monoclonal PG2B8F against the trisaccharide portion of this antigen.
In summary, we have developed a system for producing human monoclonal antibodies against M. leprae antigens. The main advantage of these human reagents will be in the study of idiotype regulation in leprosy patients.
